ApconiX is delighted to welcome Dr Laurence Bishop to the team as our Head of Business Development. Laurence is an experienced DMPK and toxicological scientist with 20 years’ experience of nonclinical drug development. Specialising in business development for the past 13 years, we are looking forward to Laurence playing a key role in our growth [...]
ApconiX is pleased to announce that Dr Guy Healing has been appointed to an Honorary Professorship in the School of Pharmacy at the University of East Anglia (UEA), Norwich, UK. Guy first became involved with the UEA when he worked for AstraZeneca. One of the University’s PhD projects was co-sponsored by AstraZeneca and Guy was [...]
ApconiX welcomes Dr Selvan Bavan, who joins us to carry out ion channel research using manual patch-clamp while learning more about using automated patch-clamp by working with Dr Michael Morton and Dr Karen Jones. Selvan commented, “Conventional manual patch-clamp is regarded as a ‘gold standard’ technique to record ion channel currents, but this technique has [...]
As we all continue to live through these very difficult times, our main priority is the safety and wellbeing of our staff, their families and the community. As an essential facility in the development of new medicines, we remain fully operational. We are following government guidelines and are keeping all our clients updated as the [...]
The meeting that ApconiX is co-organising the British Toxicology Society “Science-led Strategies for Success in Discovery and Development Toxicology” is being rearranged for a date later in 2020 - watch this space for updates! Sponsored by Lonza and AstraZeneca and co-organised by ApconiX, GlaxoSmithKline, Sygnature Discovery and Alderley Park, the meeting is focused on safety [...]
In the second of a three-part series looking at cardiac safety testing in early drug discovery, Dr Michael Morton of ApconiX considers the CiPA initiative and how its integrated approach sits alongside existing strategies. What is the CiPA initiative and what does it mean for drug discovery? In the first blog, we outlined the background [...]
ApconiX welcomes Charlotte North to the team. Charlotte graduated from Sheffield University in July with a degree in Biomedical Sciences and is working in the ApconiX Ion Channel Laboratory as an industry placement student this month. Charlotte has been spending her time, since graduating, exploring the many opportunities the pharmaceutical industry can offer. She is [...]
Phumzile Sikakana talks about ApconiX’s fundraising for 2019 and looks forward to 2020. “ApconiX have had an absolutely fantastic 6 months of fundraising for Macmillan Cancer Support. Our grand total is an amazing £2000! I'd personally like to say a massive thank you to everyone that has supported us, and I hope you’ve had as [...]
Introduction: Detection of neurotoxicity induced by prospective new therapies represents a major challenge due to the morphological and physiological complexity of the central nervous system (CNS). Characterised by uncontrolled electrical activity in the brain, seizure liability remains a significant cause of attrition in drug discovery and development. An industry survey published in 2016 reported that [...]
Abstract: Drug-induced liver injury (DILI) is of significant concern to drug development and regulatory review because of the limited success with existing preclinical models. For developing alternative methods, a large drug list is needed with known DILI severity and toxicity. We augmented the DILIrank data set [annotated using US Food and Drug Administration (FDA) drug [...]
